Ripple has released 1 billion XRP from escrow as part of its monthly supply management plan, while the token's price continues to slide in a weak broader crypto market.
From Mussolini's Rome-Berlin Axis to Bush's 'Axis of Evil,' the term has evolved from a descriptive label to a powerful political tool, framing global rivalries and shaping diplomatic realities.
As cocoa futures pull back from historic highs, Morgan Stanley boosts its price target for snack giant Mondelez International, citing improved earnings visibility. The firm maintains an Overweight rating, highlighting the company's resilient financials and shareholder returns amidst lingering sales growth uncertainties.
Investment firm Giverny Capital Asset Management detailed its sale of Fiserv shares in its 2025 year-end letter, pointing to market fixation on artificial intelligence and the financial technology giant's steep decline. The move highlights a broader divergence between fundamental performance and current investor sentiment.
Investment firm Giverny Capital Asset Management has sold its position in Align Technology (ALGN), revealing a strategic pivot towards AI-focused equities amid a challenging year where its portfolio lagged the broader market.
Despite a 4.7% portfolio contribution from Alphabet (GOOG), Giverny Capital Asset Management's 2025 returns trailed the broader market, highlighting the challenges of a strategy focused on niche leaders amid a tech-dominated rally.
KeyBanc Capital Markets maintains a Sector Weight rating on Charter Communications, warning of heightened competitive pressures from fiber expansion and potential subscriber losses ahead of the company's Q4 earnings.
TD Cowen lowered its price target on Atlassian (TEAM) ahead of earnings, highlighting strong fundamentals in service management and cloud migration but flagging weak traction in AI as a key medium-term overhang for the stock.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Defying a challenging real estate market, Five Point Holdings LLC (FPH) reported a record annual net income for 2025, driven by strategic land transactions and growth in its management business. The company also provided a bullish outlook for 2026.
In its Q4 2025 earnings call, CNX Resources outlined a disciplined capital strategy for 2026, emphasizing operational resilience amid severe weather and providing updates on its deep Utica shale program, RNG initiatives, and hedging posture. Management signaled a focus on long-term infrastructure catalysts rather than chasing volatile spot gas prices.
Ondas Holdings' flagship Optimus drone system has received the Defense Contract Management Agency's critical 'Blue List' certification, clearing it for broader U.S. defense and national security deployment. The milestone has ignited a surge in the company's stock while prompting analysts to scrutinize its long-term path to converting regulatory approval into sustainable revenue.
Under new CEO Michael Leiters, Porsche is reportedly considering axing its planned all-electric 718 Boxster and Cayman line. The potential move, driven by development hurdles and soaring costs, signals a strategic recalibration as the automaker grapples with a sales slowdown in China and the financial weight of revising its EV roadmap.
Snowflake announces a strategic $200 million partnership with OpenAI to integrate its AI models natively into the data cloud platform. The move aims to let enterprises query and analyze proprietary data using natural language, intensifying competition in the AI-infused data management sector.
As the 2027 deadline for Swift's Case Management standard approaches, banks face a strategic inflection point. Early adopters of native processing are poised to unlock operational resilience and revenue growth, while laggards risk entrenched inefficiency and competitive decline.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
